📢 Stocks Trending NOW: #MRVL #ON #APLS #WDC #ALAB #NBIS #BFRG #MKC #KIDZ #CNTA

Stocks Under $0.10: ITRM, PLYX, AMLM, BFRG, QNCX, ADMQ March Madness Watch Getting your Trinity Audio player ready... A group of sub-$0.10 and low-priced small-cap stocks is drawing increased attention as investors rotate into high-beta, low-float names across biotechnology,...

The Street Reports Sub-$0.10
thestreetreports.com/stocks-under...
#AMLM #BFRG #ADMQ #ITRM #PLYX #QNCX

📢 Stocks Trending NOW: #RZLV #ELAB #XOM #BFRG #ITRM #AA #SYY #FRMI #VRDN #SGML

A top-5 drugmaker taps BullFrog AI to hunt depression targets The customer gets exclusive access to one target candidate, using BullFrog AI's platform to speed drug discovery and clinical development in MDD.

#BFRG #BFRGW BullFrog AI Announces Commercial Agreement with Top 5 Global Pharmaceutical Company to Identify and Prioritize Therapeutic Target in Major Depressive Disorder

www.stocktitan.net/news/BFRG/bull-frog-ai-a...

BullFrog AI Publishes Annual Letter to Shareholders BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company

#BFRG #BFRGW BullFrog AI Publishes Annual Letter to Shareholders

www.stocktitan.net/news/BFRG/bull-frog-ai-p...

#BFRG #BFRGW BullFrog AI Publishes Whitepaper on AI in Bioinformatics: Turning Complex Data into Actionable Insights

www.stocktitan.net/news/BFRG/bull-frog-ai-p...

BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module BullFrog AI (NASDAQ: BFRG) announced the expansion of its internal sales organization to accelerate the commercialization of its clinical trial optimization solutions, including the recently launched bfPREP™ module. This expansion complements their existing partnership with Sygnature Discovery for BullFrog Data Networks™.The dual-pronged commercial strategy includes: 1) Sygnature partnership focusing on selling target selection solutions to global biopharma clients, and 2) Direct sales team marketing bfPREP and clinical trial optimization tools. The bfPREP module, initially developed for Eleison Pharmaceuticals collaboration, standardizes diverse clinical trial data into analyzable formats within days.

#BFRG #BFRGW BullFrog AI Expands Sales and Marketing Team to Accelerate Commercial Adoption of Clinical Trial Optimization Solutions and bfPREP™ Module

www.stocktitan.net/news/BFRG/bull-frog-ai-e...

BullFrog AI and Sygnature Discovery Announce Official Sales Launch of BullFrog Data Networks™ to Global Biopharma Clients BullFrog AI (NASDAQ: BFRG) has officially launched commercial sales of its BullFrog Data Networks™ platform through its partnership with Sygnature Discovery. The launch, which began on September 12, represents a potential $15-30 million revenue opportunity through 2028.The AI-driven platform, designed for drug development and discovery, will be marketed to Sygnature's global biopharma client base. The platform's capabilities include target identification, mechanism-of-action analysis, patient stratification, drug repurposing, and clinical trial optimization. Sygnature's business development team has completed training to integrate BullFrog Data Networks™ into their drug discovery solutions portfolio.

#BFRG #BFRGW BullFrog AI and Sygnature Discovery Announce Official Sales Launch of BullFrog Data Networks™ to Global Biopharma Clients

www.stocktitan.net/news/BFRG/bull-frog-ai-a...

Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23 BullFrog AI Holdings (NASDAQ: BFRG) announces an exclusive investor webinar scheduled for July 23, 2025, at 4:15 p.m. ET. The event, hosted by RedChip Companies, will feature CEO Vin Singh discussing the company's AI-driven drug development platforms.Key highlights include the recently launched BullFrog Data Networks™ Solutions Library, powered by their proprietary bfLEAP™ causal AI engine, and the new bfPREP™ module for automated data processing. The company will also discuss its strategic partnership with Sygnature Discovery, aimed at expanding international presence in the $204 billion biopharma R&D market.

#BFRG #BFRGW Join BullFrog AI’s Exclusive Live Investor Webinar and Q&A Session on July 23

www.stocktitan.net/news/BFRG/join-bull-frog...

BullFrog AI Launches bfPREP, a New AI-Powered Data Preparation Module in Its BullFrog Data Networks Solutions Library BullFrog AI (NASDAQ: BFRG) has launched bfPREP™, a new AI-powered data preparation module within its BullFrog Data Networks™ Solutions Library. The module, developed from the company's experience in a late-stage oncology trial, addresses the challenge of preparing fragmented clinical trial data for AI analysis.bfPREP™ targets a rapidly growing market expected to reach $6.8 billion by 2029, up from $3.1 billion in 2024. The solution features biomedical-first intelligence, end-to-end automation, standards-based interoperability, and cloud-ready deployment options. It's designed to transform raw clinical, omics, and real-world datasets into analysis-ready insights, significantly reducing data preparation time from months to days.

#BFRG #BFRGW BullFrog AI Launches bfPREP, a New AI-Powered Data Preparation Module in Its BullFrog Data Networks Solutions Library

www.stocktitan.net/news/BFRG/bull-frog-ai-l...

BullFrog AI Unveils BullFrog Data Networks™ Solutions Library, Expanding Scalable AI-Powered Biomedical Insight Platform to Large Enterprises BullFrog AI (NASDAQ: BFRG) has announced the launch of its new BullFrog Data Networks™ Solutions Library, an enterprise-scale evolution of its AI-powered biomedical insights platform. Set to launch in late 2025, the platform features native deployment support across major cloud services including Google Cloud, Microsoft Azure, and AWS.The platform is organized into specialized solution modules for different aspects of drug discovery and development, leveraging the company's bfLEAP™ causal AI engine. The solution is specifically designed for large pharmaceutical and biotechnology organizations, offering scalable infrastructure for analyzing complex biomedical datasets.This development positions BullFrog AI in the rapidly growing AI drug discovery market, which is projected to reach $35.4 billion by 2034 with a 29.6% CAGR.

#BFRG #BFRGW BullFrog AI Unveils BullFrog Data Networks™ Solutions Library, Expanding Scalable AI-Powered Biomedical Insight Platform to Large Enterprises

www.stocktitan.net/news/BFRG/bull-frog-ai-u...

BullFrog AI Director Unveils Revolutionary Solutions to 88% Drug Trial Failure Rate Exclusive webinar reveals groundbreaking AI approaches to transform drug development success rates. Learn how BullFrog AI tackles the 88% trial failure challenge. Register now.

#BFRG #BFRGW BullFrog AI’s Dr. Juan Felipe Beltrán to Highlight Advanced AI Strategies in Bioinformatics at XTalks Webinar

www.stocktitan.net/news/BFRG/bull-frog-ai-s...

BullFrog AI's New Partnership Could Generate $30M Through AI-Powered Drug Discovery Platform BullFrog AI teams up with UK's Sygnature Discovery to expand its AI drug development platform. Partnership projects $15-30M revenue through 2028. See growth strategy.

#BFRG #BFRGW BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients

www.stocktitan.net/news/BFRG/bull-frog-ai-a...

BullFrog AI CEO to Showcase Johns Hopkins-Backed Drug Development Platform That's Revolutionizing Biopharma Get exclusive insights into BullFrog AI's R&D 100 finalist platform. CEO reveals dual revenue strategy and Johns Hopkins partnership details. Register now.

#BFRG #BFRGW Join Bullfrog AI’s Exclusive Live Investor Webinar and Q&A Session on April 23

www.stocktitan.net/news/BFRG/join-bullfrog-...

BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial BullFrog AI Holdings (NASDAQ: BFRG) has entered into a collaboration agreement with Eleison Pharmaceuticals to optimize their Phase 3 clinical trial. The partnership will utilize BullFrog's Data Networks™ AI solution, powered by the bfLEAP® platform, to analyze clinical data from Eleison's ongoing Phase 3 trial of glufosfamide for pancreatic cancer.The AI platform will focus on:Evaluating trial trajectory regarding safety signalsExtracting predictive biomarkers for efficacy and safetySupporting future trial designProviding data-driven insights for Eleison's planned clinical trialsGlufosfamide, a third-generation alkylating agent, is being evaluated for second-line treatment of pancreatic cancer, which affects over 67,000 Americans and 510,000 people worldwide annually, with five-year survival rates below 5%. Eleison expects to complete the Phase 3 trial in 2027.

#BFRG #BFRGW BullFrog AI and Eleison Pharmaceuticals Enter Agreement to Collaborate to Optimize Pivotal Phase 3 Trial

www.stocktitan.net/news/BFRG/bull-frog-ai-a...

BullFrog AI Expands AI Platform, Secures Johns Hopkins Tech License & Advances Drug Pipeline BullFrog AI strengthens bfLEAP™ platform with Johns Hopkins AI tech, advances BF-114 for obesity treatment, and raises $8.83M to accelerate drug development initiatives.

#BFRG #BFRGW BullFrog AI Issues Letter to Stockholders

www.stocktitan.net/news/BFRG/bull-frog-ai-i...